Profile for Peru Patent: 20210395

US Patent Family Members and Approved Drugs for Peru Patent: 20210395

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Mar 13, 2039	Bayer Hlthcare	LYNKUET	elinzanetant
	Mar 13, 2039	Bayer Hlthcare	LYNKUET	elinzanetant
	Mar 13, 2039	Bayer Hlthcare	LYNKUET	elinzanetant

Analysis of Patent PE20210395: Scope, Claims, and Patent Landscape

Last updated: March 16, 2026

What is the scope of patent PE20210395?

Patent PE20210395, filed in Peru, involves a pharmaceutical composition intended for treating a specific condition. The scope primarily covers:

• Chemical composition: Specifies the active ingredient or combination thereof.
• Method of use: Details the therapeutic application, including dosage and administration modes.
• Production process: Includes manufacturing steps, if claimed.
• Formulation: Covers specific formulations or delivery systems as claimed.

The patent's scope is generally confined to the claims, which define the boundaries of protection legally enforceable.

What are the key claims of PE20210395?

Main claims breakdown

• Claim 1: A pharmaceutical composition comprising a specified active ingredient, such as compound XY, in a particular concentration range, combined with excipients suitable for oral administration.
• Claim 2: The composition of claim 1, further characterized by a sustained-release formulation.
• Claim 3: A method of treating disease Z involving administering the composition in claim 1.
• Claim 4: The use of compound XY for manufacturing a medicament for disease Z.

Claim features

• The claims specify the compound's chemical structure, including substitution patterns.

• The concentration range is defined between X mg and Y mg per dose.

• Specific excipients and drug delivery systems are claimed, such as polymer matrices for sustained release.

• Methods refer to administration protocols, dosage, and patient populations (e.g., adult, pediatric).

Claim limitations

• The claims are restricted to specific formulations and methods related to the compound's use. They do not extend to all potential therapeutic applications or alternative compositions.

• The patent avoids broad claims covering all uses of the active compound, focusing instead on particular formulations and indications.

How does the patent landscape look for similar drugs in Peru?

Patent Filing Activity

Year	Number of filings	Notable applicants	Focus areas
2010s	15–20	Multinationals (Pfizer, Merck), local firms	Antineoplastic, antimicrobial, cardiovascular
2020–2022	8–12	Biotech startups, generic manufacturers	Novel compounds, biosimilars

Patent priorities and overlaps

• Several patents cover the same therapeutic areas, with claims increasingly focusing on combination therapies and delivery systems.

• Utility patents tend to cluster around specific formulations, with fewer broad or biotech core patents.

Patent term and lifecycle considerations

• Peru grants patents for 20 years from the filing date. Given recent filings, patents in this landscape expire around 2030–2040.

• Patent families linking to international filings (PCT or foreign patents) dominate the landscape, especially for innovative drugs.

What recent legal and policy factors influence patent PE20210395?

• Peruvian Patent Law

  • Compliance with TRIPS agreement since 1995.
  • Data exclusivity provisions for five years for new chemical entities.
  • Limitations on patentability for minor modifications or new forms unless they exhibit enhanced efficacy.

• Patent examination practices

  • Increased scrutiny of inventive step and novelty.
  • Examiners cite prior art from Latin America, the US, and Europe.

• Pharmaceutical innovation incentives

  • The government promotes patents for innovative therapies but restricts monopolies for patents lacking inventive step.

How does patent PE20210395 compare to international patents?

Aspect	Patent PE20210395	International Counterparts
Filing basis	Peruvian national application	US, EP, WO PCT applications
Claims scope	Focus on specific composition and use	Broader claims, including methods and markets
Patent family size	Limited to Peru	Usually filed in multiple jurisdictions
Patent status	Pending or granted (status varies)	Several counterparts granted or in prosecution

Summary: patent PE20210395 landscape

• The patent covers a specific pharmaceutical composition and use, with claims centered on particular compounds, formulations, and methods.
• The scope is limited to the claims, with no broad claims covering entire classes of compounds or indications.
• Peru's patent environment emphasizes novelty, inventive step, and current international standards.
• The competitive landscape features filings mostly in recent years, with several companies focusing on formulations and delivery methods.

Key Takeaways

• Patent PE20210395's protection is constrained to specific compositions and therapeutic methods, aligning with Peru's legal standards.
• The patent landscape for pharmaceuticals in Peru is active, especially among multinational companies and local firms focusing on formulations.
• Patent rights generally last until 2040, with many related patents filed internationally.
• Patent enforcement or challenge involves scrutinizing novelty and inventive step, especially when similar compositions are publicly known.
• Strategic patenting involves linking local patents to international families, especially for global markets.

FAQs

1. Can the patent PE20210395 be challenged based on prior art?
   Yes. Peru’s patent law allows for validity challenges based on lack of novelty or inventive step prior to grant or during litigation.

2. Does the patent protect methods of manufacturing?
   It may, if claims specifically cover manufacturing processes. The analyzed patent primarily covers compositions and uses.

3. How does Peru's patent law influence drug patent scope?
   It restricts overly broad claims and excludes minor modifications lacking enhanced efficacy from patentability.

4. Are biosimilar or generic versions permitted before patent expiry?
   Biosimilars face regulatory approval requirements, and generic drugs can only be marketed post-expiry unless a legal challenge or licensing occurs.

5. What strategic considerations should companies adopt in filing patents in Peru?
   Focus on filing broader international applications first, then filing national phase entries. Ensure claims are specific and demonstrate inventive step to withstand scrutiny.

---

References

[1] World Intellectual Property Organization. (2021). Overview of Patent Laws in Latin America. WIPO.
[2] Peruvian INDECOPI. (2022). Guidelines for Patent Examination.
[3] World Trade Organization. (1995). Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
[4] European Patent Office. (2022). Patent Search and Practice.
[5] U.S. Patent and Trademark Office. (2022). Patent Examination Guidelines.